secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Health, Inc. (ODYY)
CIK:        0001626644
Form:       8-K
Filed at:   2026-05-11T21:10:17+00:00
Accession:  0001683168-26-003682
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Health's sublicense deal for BreastCheck cancelled by NeuRX due to breach of Davion contract
--------------------------------------------------------------------------------

- NeuRX revoked its Oct 2025 agreement with Odyssey to sublicense Davion's BreastCheck product, effective immediately.
- NeuRX admits it lacked legal right to sublicense without Davion's written consent; Davion would have declined approval.
- Cancellation follows notice that NeuRX breached representations and warranties in the definitive agreement.
- Davion demands Odyssey withdraw public statements that it holds a BreastCheck sublicense.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626644/000168316826003682/0001683168-26-003682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626644/000168316826003682/odyssey_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-003682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer